Skip to Content
Merck
CN
  • Heterogeneity of coenzyme Q10 deficiency: patient study and literature review.

Heterogeneity of coenzyme Q10 deficiency: patient study and literature review.

Archives of neurology (2012-04-12)
Valentina Emmanuele, Luis C López, Luis López, Andres Berardo, Ali Naini, Saba Tadesse, Bing Wen, Erin D'Agostino, Martha Solomon, Salvatore DiMauro, Catarina Quinzii, Michio Hirano
ABSTRACT

Coenzyme Q(10) (CoQ(10)) deficiency has been associated with 5 major clinical phenotypes: encephalomyopathy, severe infantile multisystemic disease, nephropathy, cerebellar ataxia, and isolated myopathy. Primary CoQ(10) deficiency is due to defects in CoQ(10) biosynthesis, while secondary forms are due to other causes. A review of 149 cases, including our cohort of 76 patients, confirms that CoQ(10) deficiency is a clinically and genetically heterogeneous syndrome that mainly begins in childhood and predominantly manifests as cerebellar ataxia. Coenzyme Q(10) measurement in muscle is the gold standard for diagnosis. Identification of CoQ(10) deficiency is important because the condition frequently responds to treatment. Causative mutations have been identified in a small proportion of patients.

MATERIALS
Product Number
Brand
Product Description

USP
Ubidecarenone, United States Pharmacopeia (USP) Reference Standard
Supelco
Coenzyme Q10, analytical standard
Sigma-Aldrich
Coenzyme Q10, ≥98% (HPLC)
Ubidecarenone, European Pharmacopoeia (EP) Reference Standard
USP
Ubidecarenone for System Suitability, United States Pharmacopeia (USP) Reference Standard
Ubidecarenone for system suitability, European Pharmacopoeia (EP) Reference Standard